|  |  |  |
| --- | --- | --- |
|  | Progression free survival | Local recurrence free survival |
|   | Univariate HR (95%CI) | p | Multivariate HR (95%CI) | P | Univariate HR (95%CI) | p | Multivariate HR (95%CI) | P |
| Gender |  | 0.34 |  |   |  | 0.56 |  |   |
| Female | 1  |   |  |   | 1  |   |  |   |
| Male | 0.74 (0.39-1.38) |   |  |   | 0.82 (0.43-1.58) |   |  |   |
| **Age** | **1.03 (1.01-1.05)** | **0.01** | **1.03 (1.01-1.05)** | **0.010** | **1.03 (1.01-1.06)** | **0.003** | **1.04 (1.01-1.06)** | **0.002** |
| Intracranial hypertension | 0.92 (0.43-1.95) | 0.83 |  |   | 1.03 (0.48-2.22) | 0.93 |  |   |
| Motor deficit | 1.33 (0.67-2.63) | 0.41 |  |   | 1.18 (0.57-2.46) | 0.65 |  |   |
| Sensory deficit | 1.09 (0.39-3.06) | 0.88 |  |   | 0.91 (0.28-2.97) | 0.87 |  |   |
| Epilepsia | **0.43 (0.15-1.20)** | **0.11** |  |  | **0.49 (0.17-1.39)** | **0.18** |  |   |
| Higher function disorder | **1.81 (0.97-3.38)** | **0.06** |  |  | **1.66 (0.86-3.19)** | **0.13** |  |   |
| Visual disorder | 1.07 (0.54-2.12) | 0.84 |  |   | 1.12 (0.55-2.30) | 0.75 |  |   |
| Cerebellar syndrome | 1.61 (0.67-3.88) | 0.29 |  |   | 1.80 (0.74-4.37) | 0.19 |  |   |
| Headache | 1.11 (0.59-2.08) | 0.74 |  |   | 0.93 (0.48-1.80) | 0.83 |  |   |
| Mitotic count ≥5 | 1.26 (0.68-2.35) | 0.47 |  |   | 1.11 (0.57-2.15) | 0.76 |  |   |
| Necrosis |  | 0.82 |  |   |  | 0.79 |  |   |
| WHO grade 1-2 | 1  |   |  |   | 1  |   |  |   |
| Grade 3 | 1.09 (0.50-2.41) |   |  |   | 0.89 (0.40-2.02) |   |  |   |
| Maximal diameter |  | 0.91 |  |   |  | 0.94 |  |   |
| < 3 cm | 1  |   |  |   | 1  |   |  |   |
| [3-5[ cm | 1.59 (0.20-12.49) |   |  |   | 1.39 (0.17-11.06) |   |  |   |
| >=5 cm | 1.52 (0.20-11.66) |   |  |   | 1.24 (0.16-9.63) |   |  |   |
| Tumor topography |  | **0.19** |  |  |  | **0.18** |  |   |
| Right-sided | **1**  |  |  |  | **1**  |   |  |   |
| Left-sided | **1.63 (0.86-3.10)** |  |  |  | **1.63 (0.83-3.20)** |   |  |   |
| Midline | **3.96 (0.49-31.84)** |  |  |  | **4.62 (0.56-37.98)** |   |  |   |
| Location |  | 0.94 |  |  |  | 0.73 |  |   |
| Supra-tentorial | 1  |   |  |   | 1  |   |  |   |
| Infra-tentorial | 1.03 (0.45-2.35) |   |  |   | 1.16 (0.50-2.65) |   |  |   |
| Pre-operative embolization | **0.09 (0.001-0.63)** | **0.10** |  |  | **0.10 (0.001-0.74)** | **0.12** |  |   |
| **Resection grade according to Simpson** |  | **0.17** |  | **0.046** |  | **0.10** |  | **0.015** |
| **Simpson 1-2 (GTR)** | **1**  |  | **1** |  | **1**  |  | **1**  |  |
| **Simpson 3-4 (STR)** | **1.97 (0.75-5.18)** |  | **2.77 (1.02-7.55)** |  | **2.26 (0.85-6.01)** |  | **3.57 (1.28-9.94)** |  |
| Post-operative radiotherapy | 1.14 (0.60-2.17) | 0.68 |  |   | 1.03 (0.53-2.00) | 0.93 |  |   |

**Table 1: Univariate and multivariate analyses of prognosis factors of recurrence and local recurrence in newly diagnosed patients with iSFT/HPC**

*Prognosis analyses according to the univariate Cox model. Significant parameters (p value <0,20) were then integrated in a multivariate analysis (significative if p value <0,05) and referred in bold. HR: Hazard ratio, 95%CI : 95% confidence interval, GTR : gross total resection, STR : subtotal tumor resection.*